Aptevo Therapeutics Inc. — fact timeline

Aptevo Therapeutics Inc. issued warrants to purchase 53,201 shares of common stock of warrant to Niowave, Inc. for combined purchase price of $5.075 per share for an aggregate purchase price of approximately $500,000.

“the Company agreed to initially issue and sell 98,522 of its shares of its common stock, par value $0.001 per share (the “Common Stock”) and accompanying warrants to purchase 53,201 shares of its common stock to Niowave in a private placement at a combined purchase price of $5.075 per share for an aggregate purchase price of approximately $500,000 (the “Initial Niowave Private Placement”).”

Aptevo Therapeutics Inc. issued 98,522 shares of common stock of common stock to Niowave, Inc. for combined purchase price of $5.075 per share for an aggregate purchase price of approximately $500,000.

“the Company agreed to initially issue and sell 98,522 of its shares of its common stock, par value $0.001 per share (the “Common Stock”) and accompanying warrants to purchase 53,201 shares of its common stock to Niowave in a private placement at a combined purchase price of $5.075 per share for an aggregate purchase price of approximately $500,000 (the “Initial Niowave Private Placement”).”

Aptevo Therapeutics Inc. entered into Investor Rights Agreement with Niowave, Inc. (effective 2026-05-25).

“Pursuant to the terms of an investor rights agreement (the “Investor Rights Agreement”) also entered into on May 25, 2026 between Niowave and the Company at the closing of the Initial Niowave Private Placement, Niowave agreed to certain transfer restrictions.”

Aptevo Therapeutics Inc. entered into Stock Purchase Agreement with Niowave, Inc. valued at approximately $500,000 (effective 2026-05-25).

“on May 25, 2026, the Company entered into a stock purchase agreement with Niowave (the “Stock Purchase Agreement”) pursuant to which the Company agreed to initially issue and sell 98,522 of its shares of its common stock, par value $0.001 per share (the “Common Stock”) and accompanying warrants to purchase 53,201 shares of its common stock to Niowave in a private placement at a combined purchase price of $5.075 per share for an aggregate purchase price of approximately $500,000 (the “Initial Niowave Private Placement”).”

Aptevo Therapeutics Inc. entered into Supply Agreement with Niowave, Inc. (effective 2026-05-25).

“In connection with the execution of the Collaboration Agreement, the parties concurrently entered into a supply agreement providing for Niowave to supply proprietary radioisotopes (including Actinium-225) to Aptevo to the extent that Niowave elects not to continue with the development program contemplated by the Collaboration Agreement at certain opt-out windows set forth therein, after any such opt-out (the “Supply Agreement”).”

Aptevo Therapeutics Inc. entered into Collaboration Agreement with Niowave, Inc. (effective 2026-05-25).

“On May 25, 2026, Aptevo Research and Development LLC (“Aptevo Research”), a subsidiary of Aptevo Therapeutics Inc. (the “Company”), and Niowave, Inc. (“Niowave”) entered into a collaboration agreement (the “Collaboration Agreement”) to collaborate on the development of a potential human therapeutic product incorporating Aptevo’s proprietary molecules (including APVO455) and Niowave’s proprietary radioisotopes (including Actinium-225).”

Aptevo Therapeutics Inc. reported preliminary financial results for the period ended March 31, 2026.

“On May 13, 2026, Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended March 31, 2026.”

Aptevo Therapeutics Inc. reported financial results for the year ended December 31, 2025.

“On March 26, 2026, Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended December 31, 2025.”

Aptevo Therapeutics Inc. issued common stock to YA II PN, LTD. for up to $60.0 million.

“to the Purchase Agreement, the Company has the right, but not the obligation, to issue and sell to Yorkville from time to time (each such occurrence, an “Advance”) up to $60.0 million (the “Commitment Amount”) of the Company’s common stock, $0.001 par value per share (“Common Stock”), during the 36 months following the execution of the Purchase Agreement,”

Aptevo Therapeutics Inc. entered into Standby Equity Purchase Agreement with YA II PN, LTD. valued at up to $60.0 million (effective 2026-01-08).

“On January 8, 2026, Aptevo Therapeutics Inc. (the "Company") entered into a Standby Equity Purchase Agreement (the "Purchase Agreement") with YA II PN, LTD., a Cayman Islands exempt limited company ("Yorkville"). Pursuant to the Purchase Agreement, the Company has the right, but not the obligation, to issue and sell to Yorkville from time to time (each such occurrence, an "Advance") up to $60.0 million (the "Commitment Amount") of the Company's common stock”

Aptevo Therapeutics Inc.: Amendment to Certificate of Incorporation to effect a 1-for-18 reverse stock split (effective 2025-12-29).

“Accordingly, on December 29, 2025, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect the Reverse Stock Split. The Amendment was effective at 5:01 p.m. Eastern Time on December 29, 2025 (the “Effective Time”).”

Aptevo Therapeutics Inc. engaged Baker Tilly US, LLP as its auditor.

“the Audit Committee of the Company’s Board of Directors approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm for the year ending December 31, 2025”

Moss Adams LLP resigned as auditor of Aptevo Therapeutics Inc..

“On June 23, 2025, Aptevo Therapeutics Inc., (the "Company") was notified that Moss Adams LLP ("Moss Adams"), the Company's independent registered public accounting firm, merged with Baker Tilly US, LLP effective on June 3, 2025.”

Aptevo Therapeutics Inc.: Amended certificate of incorporation to effect a 1-for-20 reverse stock split of common stock, filed and effective May 23, 2025 (effective 2025-05-23).

“On May 21, 2025, the Board approved an amendment to the Certificate of Incorporation to effect a reverse stock split of its common stock at the reverse split ratio of 1-for-20 (the “Reverse Stock Split”). Accordingly, on May 23, 2025, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect the Reverse Stock Split. The Amendment was effective at 5:01 p.m. Eastern Time on May 23, 2025 (the “Effective Time”).”

Aptevo Therapeutics Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 22, 2025, Aptevo Therapeutics Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. On its Quarterly Report for the quarterly period ended March 31, 2025, the Company reported stockholders’ deficit of $1,473,000, and, as a result, does not currently satisfy Nasdaq Listing Rule 5550(b)(1). Nasdaq’s letter has no immediate impact on the listing o”

Aptevo Therapeutics Inc.: Amended certificate of incorporation to effect a 1-for-37 reverse stock split (effective 2024-12-03).

“Accordingly, on December 2, 2024, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect the Reverse Stock Split. The Amendment was effective at 5:01 p.m. Eastern Time on December 3, 2024 (the “Effective Time”).”

Aptevo Therapeutics Inc. reported the quarter ended March 31, 2024 results: net income a net loss of $6.8 million or $9.95 per share, EPS $9.95 per share.

“Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies, today reported financial results for the quarter ended March 31, 2024 and provided a business update.”

Aptevo Therapeutics Inc. reported financial results for year ended December 31, 2023.

“Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended December 31, 2023.”

Aptevo Therapeutics Inc.: Amended certificate of incorporation to effect a 1-for-44 reverse stock split (effective 2024-03-05).

“On March 4, 2024, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-44 reverse stock split of the Company’s outstanding common stock. The Amendment was effective at 5:01 p.m. Eastern Time on March 5, 2024 (the “Effective Time”).”

Aptevo Therapeutics Inc. shareholders approved To approve, in accordance with Nasdaq Listing Rule 563(d), the issuance of more than 19.99% of the Company’s outstanding common stock, par value $0.001 per share, issuable upon the exercise of New Series A-2 Warrants and New Series B-2 Warrants with the right for such potential exercise to occur imm at the 2024-02-05 meeting.

“Proposal 2: To a pprove, in accordance with Nasdaq Listing Rule 563(d), the issuance of more than 19.99% of the Company’s outstanding common stock, par value $0.001 per share, issuable upon the exercise of New Series A-2 Warrants and New Series B-2 Warrants with the right for such potential exercise to occur immediately following the date upon which stockholders approve this proposal. FOR AGAINST ABSTAIN BROKER NON-VOTES 3,977,073 1,495,805 26,255 4,165,788”

Aptevo Therapeutics Inc. shareholders approved To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio in the range of 1-for-15 to 1-for-44, with such ratio to be determined in the discretion of the Board and with such reverse stock split at the 2024-02-05 meeting.

“Proposal 1: To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company common stock at a ratio in the range of 1-for-15 to 1-for-44, with such ratio to be determined in the discretion of the Board and with such reverse stock split to be effected at such time and date, if at all, as determined by the Board in its sole discretion. FOR AGAINST ABSTAIN BROKER NON-VOTES 7,159,500 2,477,700 27,721 0”

Aptevo Therapeutics Inc. reported the quarter ended September 30, 2023 results: net income net loss of $6.3 million or $0.50 per share, EPS $0.50 per share.

“Aptevo had a net loss of $6.3 million or $0.50 per share for the three months ended September 30, 2023, compared to a net loss of $7.6 million or $1.50 per share for the corresponding period in 2022.”

Aptevo Therapeutics Inc. entered into Inducement Agreement with certain holders of existing Series A Common Stock Purchase Warrants and Series B Common Stock Purchase Warrants valued at up to approximately $3.4 million (effective 2023-11-09).

“On November 9, 2023, Aptevo Therapeutics Inc. (the “Company”) entered into a warrant inducement agreement (the “Inducement Agreement”) with certain holders (the “Holders”) of the Company’s existing Series A Common Stock Purchase Warrants (“Existing Series A Warrants”) and Series B Common Stock Purchase Warrants (“Existing Series B Warrants” and together, the “Existing Warrants”) to purchase shares of common stock, par value $0.001 per share (the “Common Stock”), of the Company.”

Aptevo Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“September 13, 2023, Aptevo Therapeutics Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until March 11, 2024 (the “Compliance Date”), to regain compliance with”

Aptevo Therapeutics Inc. reported financial results for the quarter ended June 30, 2023.

“On August 10, 2023, Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended June 30, 2023.”

Aptevo Therapeutics Inc. shareholders approved Approval, on a non-binding advisory basis, of the Company's named executive officer compensation as disclosed in the Proxy Statement at the 2023-06-02 meeting.

“FOR AGAINST ABSTAIN BROKER NON-VOTES 969,344 332,792 8,095 2,566,806”

Aptevo Therapeutics Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm for 2023 at the 2023-06-02 meeting.

“FOR AGAINST ABSTAIN 3,581,428 276,500 19,109”

Aptevo Therapeutics Inc. shareholders approved Election of Directors at the 2023-06-02 meeting.

“The following two nominees, each of whom were named in the Proxy Statement, were elected to serve on the Board of Directors to hold office until the 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, based on the following votes: FOR WITHHELD BROKER NON-VOTES Zsolt Harsanyi, Ph.D. 967,133 343,098 2,566,806 Barbara Lopez Kunz 716,175 594,056 2,566,806”

Aptevo Therapeutics Inc. terminated Credit Agreement with MidCap Financial Trust with MidCap Financial Trust valued at Credit agreement terminated upon full repayment of all indebtedness (effective 2023-03-29).

“On March 29, 2023, in connection with the closing of the Purchase Agreement, the Company repaid in full all indebtedness, liabilities and other obligations under, and terminated, that certain Credit Agreement by and between the Company and MidCap Financial Trust ("MidCap"), dated August 5, 2020 as amended from time to time.”

Aptevo Therapeutics Inc. entered into Payment Interest Purchase Agreement with XOMA (US) LLC valued at $9,600,000 at closing plus up to $50,000 post-closing (effective 2023-03-29).

“On March 29, 2023, the Company entered into and closed a payment interest purchase agreement (the "Purchase Agreement") with XOMA (US) LLC ("XOMA") pursuant to which the Company sold to XOMA its right, title and interest in and to all of the Deferred Payments and a portion of the Milestone Payments.”

Aptevo Therapeutics Inc. reported year ended December 31, 2022 results: revenue $22.6 million.

“preliminary results from the study later this year.” 3 2022 Summary Financial Results Cash Position: Aptevo had cash and cash equivalents as of December 31, 2022 totaling $22.6 million. Royalty Revenue: Royalty revenue for the period covered by this report reflects revenue recorded only in the first quarter of 2022 due to our Amendment to Royalty Purchase”

Daphne Taylor was appointed as Senior Vice President, Chief Financial Officer at Aptevo Therapeutics Inc..

“Also, on March 3, 2023, the Company appointed Daphne Taylor, formerly the Company’s Senior Vice President, Finance, to Senior Vice President, Chief Financial Officer.”

Jeffrey G. Lamothe was appointed as Executive Vice President, Chief Operating Officer at Aptevo Therapeutics Inc..

“On March 3, 2023, Aptevo Therapeutics Inc. (the “Company”) appointed Jeffrey G. Lamothe, formerly the Company’s Executive Vice President, Chief Financial Officer, to Executive Vice President, Chief Operating Officer.”

Aptevo Therapeutics Inc. amended "Rights Agreement" with Broadridge Corporate Issuer Solutions, Inc. valued at 1011 (effective 2022-11-04).

“On November 4, 2022, Aptevo Therapeutics Inc. (the “Company”) entered into Amendment No. 2 (the “Amendment”) to the Rights Agreement, dated as of November 8, 2020, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent, as amended on November 5, 2021 (the “Rights Agreement”).”

John Niederhuber was appointed as Chairman of the Board at Aptevo Therapeutics Inc..

“On January 21, 2022, the Board appointed John Niederhuber, M.D. as Chairman of the Board effective April 1, 2022.”

Fuad El-Hibri departed as Chairman of the Board at Aptevo Therapeutics Inc..

“On January 21, 2022, Fuad El-Hibri, Chairman of the Board of Directors (“Board”) of Aptevo Therapeutics Inc. (“Company”), notified the Company of his retirement and resignation as a director of the Company, effective April 1, 2022.”

Jane Gross resigned as Chief Scientific Officer at Aptevo Therapeutics Inc..

“On August 25, 2021, Jane Gross (“Gross”) resigned as the Chief Scientific Officer of Aptevo Therapeutics Inc. (the “Company”) effective September 14, 2021 (“Separation Date”)”